Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-11-28, Stock:JNJ, The news for the past five days is as follows:
2018-11-20: NEWS1: Dow Sinks 551 Points as Tech, Retail, Oil Sell Off.NEWS2: Dow Sinks 551 Points as Tech, Retail, Oil Sell Off.NEWS3: Market Close Report: NASDAQ Composite index closes at 6,908.82 down -119.66 points.NEWS4: Market Close Report: NASDAQ Composite index closes at 6,908.82 down -119.66 points.NEWS5: Glaxo Seeks Label Expansion of Nucala in Pediatric Patients.NEWS6: Merck’s Stock Price Has Increased ~34% in 2018.NEWS7: Here's What's Actually Working as the Market Sells Off: Charts.NEWS8: Dow Movers: BA, VZ.NEWS9: Dow Movers: BA, VZ.NEWS10: 5 Dow Stocks to Sell (And 2 to Buy).NEWS11: 5 Companies Hit 52-Week Highs.NEWS12: Health Care Sector Update for 11/20/2018: ORPN, BLRX, BSX, JNJ, PFE, ABT, MRK, AMGN.NEWS13: Health Care Sector Update for 11/20/2018: ORPN, BLRX, BSX, JNJ, PFE, ABT, MRK, AMGN.NEWS14: The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings.NEWS15: Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know.NEWS16: Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know.
2018-11-21: NEWS1: Dow Surrenders Triple-Digit Lead; Tech Helps Nasdaq Higher.NEWS2: Dow Surrenders Triple-Digit Lead; Tech Helps Nasdaq Higher.NEWS3: Market Close Report: NASDAQ Composite index closes at 6,972.25 up 63.43 points.NEWS4: Market Close Report: NASDAQ Composite index closes at 6,972.25 up 63.43 points.NEWS5: Stock Market Rally Dampened As Dow Gives Up 200-Point Gain.NEWS6: Health Care Sector Update for 11/21/2018: BPMC,CYAD,SYN,JNJ.NEWS7: Health Care Sector Update for 11/21/2018: BPMC,CYAD,SYN,JNJ.NEWS8: U.S. appeals court declines J&J bid to stop generic Zytiga sales.NEWS9: Health Care Sector Update for 11/21/2018: CYAD,SYN,JNJ.NEWS10: Health Care Sector Update for 11/21/2018: CYAD,SYN,JNJ.NEWS11: 5 Top Stock Trades to Mull Over Thanksgiving.NEWS12: J&J Falls After Failing to Block Generic Zytiga Cancer Drug.NEWS13: Johnson & Johnson&apos;s stock drops to pace Dow decliners after appeals court ruling on Zytiga disappoints.NEWS14: Theravance JAK Inhibitor Enters Phase II for Crohn's Disease.NEWS15: Theravance JAK Inhibitor Enters Phase II for Crohn's Disease.NEWS16: Shire-Takeda Deal Gets Phase I Conditional European Approval.NEWS17: Shire-Takeda Deal Gets Phase I Conditional European Approval.NEWS18: Mylan Recalls Valsartan Lots, Gets FDA Warning for Facility.NEWS19: Mylan Recalls Valsartan Lots, Gets FDA Warning for Facility.NEWS20: Dow Movers: JNJ, CAT.NEWS21: Dow Movers: JNJ, CAT.NEWS22: S&P 500 Movers: JNJ, FL.NEWS23: S&P 500 Movers: JNJ, FL.NEWS24: Theravance JAK Inhibitor Enters Phase II for Crohn's Disease.NEWS25: Can Deal Interest Help Tesaro Recover?.NEWS26: Can Deal Interest Help Tesaro Recover?.NEWS27: Analysts Remain Bullish on Stryker Stock.NEWS28: Understanding Stryker’s Operational Performance.NEWS29: How Stryker Is Positioned in November.NEWS30: Mylan Recalls Valsartan Lots, Gets FDA Warning for Facility.NEWS31: Health Care Sector Update for 11/21/2018: SYN, CYAD, JNJ, PFE, ABT, MRK, AMGN.NEWS32: Health Care Sector Update for 11/21/2018: SYN, CYAD, JNJ, PFE, ABT, MRK, AMGN.NEWS33: Shire-Takeda Deal Gets Phase I Conditional European Approval.NEWS34: Can Deal Interest Help Tesaro Recover?.NEWS35: Today's Research Reports on Trending Tickers: Johnson & Johnson and Merck & Co..NEWS36: Capitalism Is Working in the U.S..
2018-11-23: NEWS1: Bayer Hurts from Generic Competition & Pipeline Setbacks.NEWS2: Bayer Hurts from Generic Competition & Pipeline Setbacks.NEWS3: Bayer Hurts from Generic Competition & Pipeline Setbacks.NEWS4: Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs.NEWS5: Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs.NEWS6: Dow 30 Stock Roundup: Boeing to Supply 40 737 MAX 8 to Jeju Air, Pfizer Gets FDA Nod.NEWS7: Dow 30 Stock Roundup: Boeing to Supply 40 737 MAX 8 to Jeju Air, Pfizer Gets FDA Nod.NEWS8: Gauging Analysts’ Views on Tesaro Stock.NEWS9: Understanding Tesaro’s Gross Margin Trend.NEWS10: Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for November 26, 2018.NEWS11: Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for November 26, 2018.NEWS12: Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs.NEWS13: Dow 30 Stock Roundup: Boeing to Supply 40 737 MAX 8 to Jeju Air, Pfizer Gets FDA Nod.NEWS14: Today's Research Reports on Trending Tickers: Altimmune and Johnson & Johnson.
2018-11-26: NEWS1: Spinal-cord stimulators help some patients, injure others.NEWS2: AMAG's Label Expansion of Lead Products Raises Share Price.NEWS3: One Put, One Call Option To Know About for Johnson & Johnson.NEWS4: One Put, One Call Option To Know About for Johnson & Johnson.NEWS5: Dow Movers: JNJ, AXP.NEWS6: Dow Movers: JNJ, AXP.NEWS7: Osiris Therapeutics Names Samson Tom CEO.NEWS8: Osiris Therapeutics Names Samson Tom CEO.NEWS9: The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca.NEWS10: The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca.NEWS11: Glaxo Inks Marketing Deal for Anaemia Candidate in Japan.NEWS12: Gauging Analysts’ Views on Zoetis Stock.NEWS13: Understanding Zoetis’s Gross Margin Trend.NEWS14: Glaxo Inks Marketing Deal for Anaemia Candidate in Japan.NEWS15: The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca.NEWS16: Phibro Animal Health Corporation (PAHC) Ex-Dividend Date Scheduled for November 27, 2018.NEWS17: Phibro Animal Health Corporation (PAHC) Ex-Dividend Date Scheduled for November 27, 2018.NEWS18: Johnson & Johnson to Participate in the BMO Prescriptions for Success Healthcare Conference.NEWS19: [$$] Microsoft: Wall Street’s most resilient mega-cap?.NEWS20: Spinal-cord stimulators help some patients, injure others.
2018-11-27: NEWS1: Why Celgene's Blockbuster Cancer Drug Looks Safe — For Now.NEWS2: Dow Analyst Moves: JNJ.NEWS3: Dow Analyst Moves: JNJ.NEWS4: Novartis's Alcon sees myopia epidemic driving sales growth.NEWS5: Glaxo (GSK) and J&J's HIV Drug Juluca Gets Approval in Japan.NEWS6: Glaxo (GSK) and J&J's HIV Drug Juluca Gets Approval in Japan.NEWS7: 3 Reasons Why Glaxo (GSK) Stock is Up This Year So Far.NEWS8: 3 Reasons Why Glaxo (GSK) Stock is Up This Year So Far.NEWS9: Noteworthy ETF Inflows: IWD, JPM, XOM, JNJ.NEWS10: Noteworthy ETF Inflows: IWD, JPM, XOM, JNJ.NEWS11: 3 Reasons Why Glaxo (GSK) Stock is Up This Year So Far.NEWS12: Glaxo (GSK) and J&J's HIV Drug Juluca Gets Approval in Japan.NEWS13: The Zacks Analyst Blog Highlights: Boeing, Microsoft, Johnson & Johnson, Chevron and Pfizer.NEWS14: The Zacks Analyst Blog Highlights: Boeing, Microsoft, Johnson & Johnson, Chevron and Pfizer.NEWS15: The Zacks Analyst Blog Highlights: Boeing, Microsoft, Johnson & Johnson, Chevron and Pfizer.NEWS16: AMAG's Label Expansion of Lead Products Raises Share Price.NEWS17: AMAG's Label Expansion of Lead Products Raises Share Price.

Answer: Rise